Moderna, Merck Announce mRNA-4157 (V940) Plus Keytruda Shows Improvement in Recurrence-Free Survival, Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
Portfolio Pulse from Benzinga Newsdesk
Moderna and Merck have announced that their collaborative treatment, mRNA-4157 (V940) combined with Keytruda, has shown improvement in recurrence-free survival and distant metastasis-free survival in patients with high-risk Stage III/IV melanoma after complete resection, compared to Keytruda alone at a three-year mark.
December 14, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's Keytruda, when used with Moderna's mRNA-4157, shows improved outcomes in melanoma treatment, which may positively influence Merck's stock performance.
The successful results from the combination of Keytruda and mRNA-4157 could enhance the market position of Keytruda and Merck's oncology portfolio. This is likely to be viewed favorably by investors, possibly leading to a short-term increase in Merck's stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Moderna's collaborative treatment with Merck, mRNA-4157, shows positive three-year results in melanoma patients, potentially boosting investor confidence and stock value.
The positive clinical trial results for mRNA-4157 in combination with Keytruda are likely to be seen as a significant advancement in Moderna's product pipeline, which could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80